A sthma and abdominal aortic aneurysms (AAA) are chronic inflammatory diseases that share many biochemical and pathological similarities. Patients or animals with asthma or AAA have elevated plasma IgE levels. 1, 2 In asthmatic patients, bronchial and alveolar accumulation of eosinophils, mast cells, macrophages, and lymphocytes indicates an important signature of the disease. 3 Similarly, in human and experimental AAA lesions, accumulation of macrophages, T cells, mast cells, and neutrophils determines the initiation and progression of this aortic disease and pathology. 4 Our recent studies demonstrated an important role of IgE in mouse experimental AAA development. In apolipoprotein E-deficient (Apoe -/-) mice, the absence of IgE receptor FcεR1 protected these mice from angiotensin II (Ang-II)-induced AAA. Anti-IgE antibody treatment also mitigated AAA progression. 2 These previous studies suggest an interaction between asthma and AAA.
The Viborg Vascular screening trial of 18 749 men from Denmark demonstrated a 45% AAA risk increase in patients with a record of an asthmatic medication prescription. Although smoking is an important risk factor of human and mouse AAA, [5] [6] [7] adjustment of cigarette smoking did not attenuate asthma-associated risk of AAA (G.-P. Shi and J.S. Lindholt, unpublished observation). The population of Danish National Registry of Patients of 15 942 men with AAA revealed a 30% to 100% aortic rupture risk increase in patients with an asthma diagnosis or experience with antiasthmatic treatments (G.-P. Shi and J.S. Lindholt, unpublished observation). These clinical observations suggest that asthma increases the risk of AAA incidence and aortic rupture. This study tested this hypothesis in Apoe -/mice. The infusion of Ang-II helps produce AAA in Apoe -/mice. 8, 9 Ovalbumin sensitization and challenge produce allergic lung inflammation (ALI) in mice. 10, 11 We produced ALI and AAA simultaneously or sequentially in Apoe -/mice to test whether the development of ALI at the same time as, before, or after AAA production affects AAA development.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ALI Promotes Experimental AAA in Mice
We first concurrently produced ALI together with Ang-II (1000 ng kg −1 min −1 )-mediated AAA in Apoe -/mice ( Figure 1A ). Compared with mock (saline)-sensitized mice, ovalbuminsensitized mice exhibited significantly enlarged maximal aortic diameters (4.34±0.46 versus 2.31±0.21 mm; P=0.001; Figure 1B ) and aortic cross-section AAA lesion areas (P=0.036) and increased lesion Mac-2 + macrophage-positive areas (P=0.044), mast cell (P=0.011) content ( Figure 1C) , media smooth muscle cell (SMC) loss (P<0.001), lesion cell proliferation (P=0.047), and microvascularization (P=0.004; Figure 1D ). Fisher exact test did not show a significant difference in post-Ang-II infusion mortality rate between the 2 groups ( Table I in the online-only Data Supplement, left) . Ovalbumin-sensitized AAA mice showed significantly higher plasma IgE (P=0.004) but reduced plasma interleukin-5 (IL-5; P=0.044) concentrations ( Figure 1E ). Bronchioalveolar lavage fluid (BALF) total inflammatory cells and leukocyte differential counts confirmed the production of ALI. Ovalbumin-sensitized AAA mice showed significantly higher total BALF inflammatory cell counts (P=0.031) and eosinophil (P=0.001; Figure 1F ) and lymphocyte (P=0.015) percentages compared with mocksensitized AAA mice, with concurrent reduction of macrophage percentages (P<0.001). In AAA mice with concurrent ALI, elevated AAA lesion sizes may associate with their high plasma IgE levels and high lesion macrophage and mast cell contents. IgE-mediated activation of macrophages and mast cells may contribute to enhanced AAA development in these mice ( Figure 1B and 1C ). 2 Allergic inflammation did not significantly affect mouse body weight, blood pressure, plasma lipid contents, or any tested BALF cytokines and chemokines, including interferon-γ (IFN-γ), tumor necrosis factor-α (TNFα), eotaxin, monocyte chemoattractant protein-1, IL-4, IL-5, IL-13, and transforming growth factor-β (TGF-β; Table I in the online-only Data Supplement, left). Asthmatic patients or ALI mice often have increased plasma IL-5 and IL-13. [12] [13] [14] Human AAA lesions and those from Ang-II-infused Apoe -/mice also revealed elevated IL-5 expression. 15, 16 Anti-IL-5 antibody reduced Ang-II-induced AAA in Apoe -/mice, 16 suggesting a proaneurysmogenic role of IL-5. Codevelopment of ALI and AAA may have increased plasma IL-5 and IL-13. Why these mice showed reduced plasma IL-5 remains unknown ( Figure 1E ). Contrast to the IL-5 expression in AAA lesions, plasma IL-5 did not differ between AAA and AAA-free patients. 17 In Apoe -/mice, IL-5 expression in Ang-II-induced AAA lesions at 28 days after Ang-II infusion did not differ from those of normal mice. 16 Therefore, multiple factors may impact the production of IL-5 or IL-13 in mice with ALI and AAA.
The second group of mice ( Figure 2A ) first underwent production of ALI and then AAA induction with Ang-II (1000 ng kg −1 min −1 ). Ovalbumin-sensitized mice again developed significantly larger aortic diameters (3.07±0.32 versus 1.95±0.24 mm; P=0.006; Figure 2B ) and cross-section lesion areas (P=0.033) when compared with mock-sensitized mice ( Table I in the online-only Data Supplement, right), although aortic rupture post Ang-II infusion did not differ between the groups. Ovalbumin-sensitized mice exhibited higher levels of lesion Mac-2 + macrophage-positive areas (P=0.007), mast cells (P<0.001), and medial SMC loss (P=0.010) compared with mock-sensitized mice ( Figure 2C and 2D). Compared with mock-sensitized mice, ovalbumin-sensitized mice had significantly higher plasma IgE levels (P=0.001) but lower anti-inflammatory plasma IL-5 (P=0.002), IL-13 (P=0.019), and TGF-β (P=0.050; Figure 2E ). Ovalbumin-sensitized AAA mice had significantly higher numbers of BALF total inflammatory cells and percentages of BALF eosinophils (P=0.026; Figure 2F ) and lymphocytes (P=0.002) but reduced percentages of macrophages (P=0.018), affirming the production of ALI ( Figure 2F ). Ovalbumin-sensitized AAA mice showed an increase in post-AAA diastolic blood pressures (P=0.035) and reduction of BALF IL-13 levels (P=0.023), but the other variables measured, including plasma lipoproteins and BALF proteins, did not differ significantly from those of mock-sensitized mice ( 
ALI Exacerbates Pre-Established AAA in Mice
We also tested whether induction of ALI after AAA production exacerbated pre-established AAA. A group of 8-to 10-weekold male Apoe -/mice did not undergo AAA induction but started ovalbumin or mock sensitization on day 29 as controls ( Figure 3A ). Control mice without AAA did not exhibit significant changes in abdominal aortic diameter (1.000±0.054 versus 1.026±0.046 mm; P=0.727), cross-section areas, or any other arterial wall pathological variables between ovalbumin-and mock-sensitized mice, except collagen content that was lower in ovalbumin-sensitized mice when compared with mock-sensitized mice (P=0.020). Ovalbumin-sensitized mice also had lower plasma total cholesterol (P=0.017) and triglyceride (P=0.040) levels compared with mock-sensitized mice ( Table II in the online-only Data Supplement, left). As anticipated, ovalbumin-sensitized Apoe -/mice had increased plasma IgE (P=0.006), IFN-γ (P=0.022), and IL-5 concentrations (P=0.033; Figure 3B ). 10, 11 Ovalbumin-sensitized mice showed higher BALF levels of total inflammatory cells (P=0.002) and percentages of eosinophils (P<0.001; Figure 3C ) and lymphocytes (P<0.001) compared with mocksensitized mice, whereas ovalbumin-sensitized mice revealed reduced macrophage percentages (P<0.001). Ovalbuminsensitized mice had higher BALF concentrations of IgE (P=0.011), TNF-α (P=0.020), monocyte chemoattractant protein-1 (P=0.004), IL-5 (P=0.004), and IL-13 (P=0.029) compared with mock-sensitized mice ( Table II in the onlineonly Data Supplement, left). Next, we produced AAA in 8-to 10-week-old male Apoe -/mice. Then, at 29 days post Ang-II infusion, animals underwent ovalbumin or mock immunization to produce airway allergic inflammation ( Figure 3D ). In Apoe -/mice that had pre-established AAA, development of ALI did not affect body weight, blood pressure, plasma lipoprotein, BALF cytokines, or blood chemokine concentrations ( Table II in the online-only Data Supplement, right). In sharp contrast, ovalbumin-sensitized mice had significantly larger aortic diameters (2.71±0.42 versus 1.49±0.14 mm; P=0.020) ( Figure 3E ), cross-section AAA lesion areas (P=0.041), lesion mast cells (P=0.012), CD4 + T cells (P=0.014), CD8 + T cells (P=0.010), medial SMC loss (P<0.001), lesional Ki67 + cells (P=0.038), and apoptotic cells (P=0.038; Figure 3F and 3G). Plasma from ovalbumin-sensitized AAA mice had increased TNF-α and reduced TGF-β concentrations. Plasma IgE levels were also higher in ovalbumin-sensitized mice than that in mock-sensitized mice, although such a difference did not reach statistical significance (0.49±0.09 versus 0.35±0.07 µg/mL; P=0.309; Figure 3H ). IgE action on mast cells and T cells contributes to AAA formation. 2 Action of IgE on elevated lesion mast cells and T cells ( Figure 3F ) may contribute to enhanced AAA in ovalbumin-sensitized mice ( Figure 3E ). Although plasma IgE concentrations with Ang-II-induced AAA in Apoe -/mice increased when compared with those in control mice, 2 ovalbumin-sensitized mice (without AAA) had similar plasma IgE concentrations as Ang-II infusion-induced AAA mice (without asthma; 0.40±0.07 versus 0.35±0.07 µg/mL; P=0.726). The ovalbumin-sensitized mice had significantly increased total inflammatory cells and eosinophils ( Figure 3H ) in BALF, affirming the production of allergic inflammation in ovalbumin-sensitized mice. Two sets of data in Table II in the online-only Data Supplement provide detailed analyses of the AAA lesions and allergic inflammation from mice presented in Figure 3A and 3D.
Pre-Established AAA Aggravates Ovalbumin-Sensitized Mouse Airway Allergic Responses
The comparison of data from ovalbumin-sensitized mice with and without AAA determined whether pre-established AAA influenced the development of ALI ( Figure 3A and 3D) . Relative to the absence of pre-existing AAA, ovalbumin-sensitized AAA mice showed significantly increased plasma concentrations of IFN-γ (P=0.011), eotaxin (P=0.015), IL-4 (P=0.005), IL-5 (P=0.048), and TGF-β (P=0.049). Ovalbumin-sensitized AAA mice also had enlarged aortic diameters (2.712±0.418 versus 1.000±0.054 mm; P=0.003), increased aortic crosssection lesion areas, higher lesion macrophages, mast cells, CD4 + T cells, and CD8 + T cells, major histocompatibility complex-II-positive areas, media SMC loss, elastin fragmentation, lesion cell proliferation and apoptosis, and microvascularization relative to ovalbumin-sensitized mice without AAA ( Table III in the online-only Data Supplement, left). BALF cell analysis showed that pre-established AAA significantly increased BALF total inflammatory cells (P=0.006), macrophages (P=0.004), lymphocytes (P=0.003), and eosinophils (P=0.030) in ovalbumin-sensitized mice. Pre-establishment of AAA did not affect most tested cytokines and chemokines in BALF. Mice with pre-established AAA ( Table III in the online-only Data Supplement, left) only showed reduced IL-5 (P=0.009) and TGF-β (P=0.011). Pre-established AAA in mock-sensitized mice increased aortic diameters (1.488±0.138 versus 1.026±0.046 mm; P=0.009), lesion areas (P=0.011), lesion macrophages (P<0.001), mast cells (P<0.001), CD4 + T cells (P<0.001), CD8 + T cells (P<0.001), the inflammatory marker major histocompatibility complex-II (P=0.009), medial SMC loss (P<0.001), elastin fragmentation grade (P<0.001), cell proliferation (P<0.001), apoptosis (P<0.001), and microvascularization (P<0.001; Table III in the onlineonly Data Supplement, right). Pre-established AAA in mocksensitized mice also increased plasma IgE (P=0.007), IFN-γ (P=0.001), TNF-α (P=0.004), eotaxin (P=0.003), and TGF-β (P=0.018), as well as lymphocytes (P=0.032). Plasma IL-4 (P=0.047) and IL-13 (P=0.012) fell, but BALF total inflammatory cells, macrophages, eosinophils, and neutrophils did not change significantly. Pre-established AAA also increased BALF IgE (P=0.005), TNF-α (P=0.001), eotaxin (P=0.006), and IL-13 (P=0.028) and reduced BALF TGF-β (P=0.004) in mock-sensitized mice ( Table III in the online-only Data Supplement, right), suggesting that AAA augments concentrations of lung inflammatory mediators.
Airway Allergic Inflammation Promotes Periaortic CaCl 2 Injury-Induced AAA
The introduction of ALI to periaortic CaCl 2 injury-induced AAA in wild-type mice helped test whether the proaneurysmogenic activity of ALI applies to other experimental AAA. Production of ALI greatly increased AAA lesion size and cross-sectional lesion area, compared with those of salinesensitized mice ( Figure 4A) , with significant increase of lesion macrophages, mast cells, media SMC loss, and lesion microvessel contents ( Figure 4B-4E) . BALF total inflammatory cell accumulation was also higher in AAA mice with ALI than in mice without ALI ( Figure 4F ). ELISA detected significantly higher plasma IgE levels in mice with both AAA and ALI than in mice with AAA but sensitized with saline, but plasma IL-5 and IL-13 levels did not differ significantly between the 2 groups of mice ( Figure 4G ). Such insignificant difference in plasma IL-5 and IL-13 levels may associate with AAA production of the 2 groups of mice. [13] [14] [15] [16] 
Anti-IgE Antibody Mitigates AAA in Mice With Airway Allergic Inflammation
Mice with concurrent development of ALI and AAA ( Figure 1A ) showed significant increase of AAA lesion size ( Figure 1B) , lesion inflammatory cell accumulation ( Figure 1C) , and plasma IgE levels ( Figure 1E ). ALI-induced plasma IgE increase may contribute to increased AAA sizes in mice with concurrent ALI and AAA. The administration of anti-IgE monoclonal antibody to Ang-II-infused mice sensitized with ovalbumin or saline tested this hypothesis. Two doses of intraperitoneal injection of anti-IgE antibody greatly reduced plasma IgE levels from both groups of mice ( Figure 4H ). In ALI mice, the significant suppression of enlarged AAA sizes and cross-section lesion areas occurred after anti-IgE antibody treatment ( Figure 4I ), as well as lesion macrophage contents ( Figure 4J ). As anticipated, the suppression of elevated inflammatory cell accumulation in BALF from ALI mice occurred after anti-IgE antibody treatment ( Figure 4K ), as previously reported. 18, 19 
Discussion
This study established an association between ALI and AAA in Ang-II-induced AAA mice. Mice with ALI from an inhaled allergen showed significantly enhanced AAA progression, before, during, or after AAA induction, although data did not show significant differences in post Ang-II infusion superarenal aortic rupture between mice with or without ALI. These observations agree with our preliminary observation from the Viborg Vascular screening trial of 619 AAA patients from 18 749 men. The lack of knowledge in interactions between allergy and AAA may be the cause of incomplete screening information specific for asthma among the AAA populations. The use of antiasthmatic prescription records helped indicate asthma among this screening population. Patients with such a prescription experienced a 45% higher AAA risk than those without (odds ratio, 1.450; 95% confidence interval, 1.096-1.918; P<0.01; G.-P. Shi and J.S. Lindholt, unpublished observation).
Allergic asthma [20] [21] [22] and AAA [23] [24] [25] involve the T-helper cell 2 cytokines IL-4, IL-5, and IL-13 and the T H1 cytokines IFN-γ and TNF-α in both humans and animals. Increased allergic airway responses augment BALF IgE and cytokines/ chemokines (TNF-α, eotaxin, monocyte chemoattractant protein-1, IL-5, and IL-13). 10, 11 Ovalbumin sensitization-and challenge-induced production of these cytokines in mice with ALI seemed to be aneurysmogenic in these mice. In this study, allergen sensitization and challenge did not change most of the tested BALF cytokines and chemokines regardless whether AIL and AAA were produced sequentially or at the same time, suggesting common mechanisms for the development of type 2 inflammation in the lung and aorta during aneurysmogenesis.
Both allergen and Ang-II infusion induced similar levels of plasma and BALF IgE. We reported previously that Ang-II infusion increased plasma IgE to 0.3 to 0.4 µg/mL. 2 This study yielded similar results. Although mice without AAA or airway allergic inflammation had plasma IgE concentrations ≈0.05 µg/mL, mice with AAA alone without allergic inflammation had plasma IgE levels of 0.35 to 0.42 µg/mL (Tables I and II in the online-only Data Supplement). These levels resemble those of mice with allergic inflammation alone without AAA that also had plasma IgE levels at 0.40 µg/mL (Table II in in experimental AAA by activating mast cells, macrophages, and CD4 + and CD8 + T cells. 2 These cells all localize in the aneurysmal mouse aorta. IgE also activates vascular SMCs and endothelial cells, promoting apoptosis of these vascular cells, 26 which contribute to aortic aneurysm formation and rupture. [27] [28] [29] Mice that receive an anti-IgE antibody (eg, Xolair) biweekly have full protection from AAA formation. 2 Here, we tested further a role of IgE in AAA. In mice with concurrent ALI and AAA, 2 doses of biweekly intraperitoneal injection of rat antimouse IgE monoclonal antibody depleted plasma IgE and significantly reduced AAA lesion size and macrophage accumulation ( Figure 4H and 4I) . Therefore, the increased plasma IgE (Figures 2E, 3E , and 4H; Table I in the online-only Data Supplement) may link ALI to AAA pathogenesis, although additional mechanisms may also contribute to the activity of ALI in inducing AAA, which requires further investigation. Anti-IgE antibody (eg, Xolair) may serve as a novel regimen for human AAA, although an appropriate dose and formulation may be required for an optimized efficacy.
This study showed that AAA development in Apoe -/mice also affected ALI, as reflected by the ≈3-fold increases in BALF total inflammatory cells, macrophages, lymphocytes, and eosinophils ( Table III in the online-only Data Supplement). Patients with AAA may bear a higher risk of developing allergic responses than AAA-free patients, a hypothesis that merits future investigation in a cohort of relevant patients. This study presented experimental mechanistic studies to establish a previously unsuspected association between ALI and AAA. Because allergic inflammation with altered T-helper cell 2 cytokine levels and elevated plasma IgE may all play detrimental roles, other allergic inflammatory diseases, such as atopic dermatitis, allergic rhinitis, and several ocular allergic diseases, might also promote AAA formation. The findings from this study highlight a commonality in the inflammatory pathways involved in AAA and other prevalent and seemingly unrelated diseases. The results have implications for the development of much-needed advances in the prevention, screening criteria, and treatment of AAA, common conditions for which we currently lack sufficiently effective approaches.
